Arachidonate 15-lipoxygenase-mediated production of Resolvin D5
ALOX15
CAF subtypes
all-trans retinoic acid
cancer-associated fibroblast
lipid mediator
pancreatic ductal adenocarcinoma
specialized pro-resolving mediator
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
06
2023
accepted:
26
10
2023
medline:
4
12
2023
pubmed:
30
11
2023
entrez:
30
11
2023
Statut:
epublish
Résumé
Activation of pancreatic stellate cells (PSCs) to cancer-associated fibroblasts (CAFs) is responsible for the extensive desmoplastic reaction observed in PDAC stroma: a key driver of pancreatic ductal adenocarcinoma (PDAC) chemoresistance leading to poor prognosis. Specialized pro-resolving mediators (SPMs) are prime modulators of inflammation and its resolution, traditionally thought to be produced by immune cells. Using liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based lipid mediator profiling PSCs as well as primary human CAFs express enzymes and receptors to produce and respond to SPMs. Human PSC/CAF SPM secretion profile can be modulated by rendering these cells activated [transforming growth factor beta (TGF-β)] or quiescent [all-
Identifiants
pubmed: 38035115
doi: 10.3389/fimmu.2023.1248547
pmc: PMC10687150
doi:
Substances chimiques
resolvin D5
0
Arachidonate 15-Lipoxygenase
EC 1.13.11.33
Tretinoin
5688UTC01R
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1248547Subventions
Organisme : Cancer Research UK
ID : C16420/A18066
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 Aguirre, Goulart, Barts Pancreas Tissue Bank, Dalli and Kocher.
Déclaration de conflit d'intérêts
Author JD is an inventor on patents related to the composition of matter and/or use of pro-resolving mediators, some of which are licensed by Brigham and Women’s Hospital or Queen Mary University of London for clinical development. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Inflamm Res. 2011 Dec;60(12):1083-92
pubmed: 21964881
NPJ Precis Oncol. 2021 Jun 29;5(1):61
pubmed: 34188166
Gastroenterology. 2011 Oct;141(4):1486-97, 1497.e1-14
pubmed: 21704588
Mol Cancer. 2005 Aug 05;4:27
pubmed: 16083499
J Pathol. 2016 Jul;239(3):286-96
pubmed: 27061193
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W652-60
pubmed: 19429898
Cell. 2021 Oct 28;184(22):5577-5592.e18
pubmed: 34644529
J Exp Med. 2005 Mar 7;201(5):713-22
pubmed: 15753205
Semin Immunol. 2015 May;27(3):200-15
pubmed: 25857211
Biochim Biophys Acta. 2015 Nov;1851(11):1465-72
pubmed: 26327594
Atherosclerosis. 1998 Feb;136(2):203-16
pubmed: 9543090
J Clin Invest. 2019 Jun 17;129(7):2964-2979
pubmed: 31205032
Cell Rep. 2020 Oct 13;33(2):108247
pubmed: 33053344
J Pathol. 2022 Jul;257(4):526-544
pubmed: 35533046
Gastroenterology. 2013 Nov;145(5):1121-32
pubmed: 23891972
J Pathol. 2019 May;248(1):51-65
pubmed: 30575030
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Mol Aspects Med. 2017 Dec;58:1-11
pubmed: 28263773
Nucleic Acids Res. 2018 Jan 4;46(D1):D1266-D1270
pubmed: 29069414
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Gut. 2019 Jan;68(1):159-171
pubmed: 30177543
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Nat Commun. 2020 Sep 24;11(1):4841
pubmed: 32973176
Circ Res. 2018 Mar 16;122(6):855-863
pubmed: 29437834
Cancer Discov. 2019 Aug;9(8):1102-1123
pubmed: 31197017
J Hepatol. 1999 Jan;30(1):77-87
pubmed: 9927153
ACS Pharmacol Transl Sci. 2020 Jan 20;3(1):88-106
pubmed: 32259091
Am J Pathol. 2012 May;180(5):2018-27
pubmed: 22449948
Am J Physiol Cell Physiol. 2014 Jul 1;307(1):C39-54
pubmed: 24696140
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12165-70
pubmed: 14530386
J Med Chem. 2015 Jan 22;58(2):537-59
pubmed: 25365541
Front Immunol. 2021 Feb 10;11:631319
pubmed: 33643307
J Clin Invest. 2021 Jun 1;131(11):
pubmed: 33905375
Cell Rep. 2022 Jan 25;38(4):110227
pubmed: 35081338
Pancreas. 2010 May;39(4):425-35
pubmed: 20418756
Gene. 2015 Nov 15;573(1):1-32
pubmed: 26216303
Nat Med. 2015 Sep;21(9):1071-5
pubmed: 26236990
Cancer Discov. 2020 Feb;10(2):232-253
pubmed: 31699795
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Clin Cancer Res. 2018 Mar 15;24(6):1344-1354
pubmed: 29288237
Cancer Cell. 2021 Sep 13;39(9):1227-1244.e20
pubmed: 34297917
J Exp Med. 2002 Oct 21;196(8):1025-37
pubmed: 12391014
Cell Mol Gastroenterol Hepatol. 2021;12(5):1543-1565
pubmed: 34252585
JCI Insight. 2019 Jul 11;4(13):
pubmed: 31292292
J Clin Oncol. 2020 Sep 20;38(27):3185-3194
pubmed: 32706635
Nat Immunol. 2001 Jul;2(7):612-9
pubmed: 11429545
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14530-5
pubmed: 25246560
Oncogene. 2009 Feb 5;28(5):773-80
pubmed: 18997822
Curr Top Microbiol Immunol. 2021;430:183-198
pubmed: 30790075
Circ Res. 2021 Aug 6;129(4):e54-e71
pubmed: 34238021
Cancer Discov. 2020 May;10(5):648-656
pubmed: 32014869
Oncogene. 2023 Feb;42(7):491-500
pubmed: 36357571
Nat Rev Cancer. 2010 Mar;10(3):181-93
pubmed: 20168319
J Pathol. 2022 Dec;258(4):408-425
pubmed: 36102377
J Immunol. 2012 Jan 1;188(1):21-8
pubmed: 22187483
J Clin Invest. 2020 Jan 2;130(1):359-373
pubmed: 31793912
J Exp Med. 2018 Jan 2;215(1):115-140
pubmed: 29191914
Prostaglandins Other Lipid Mediat. 2023 Jun;166:106718
pubmed: 36813255
Gut. 2012 Feb;61(2):172-8
pubmed: 22115911
J Clin Invest. 2018 Aug 1;128(8):3568-3582
pubmed: 30010619
Front Oncol. 2022 Jan 11;11:757073
pubmed: 35087747
J Clin Oncol. 2015 Dec 20;33(36):4284-92
pubmed: 26527777
J Clin Invest. 1995 May;95(5):2035-46
pubmed: 7738170
Trends Biochem Sci. 2007 Jul;32(7):332-41
pubmed: 17576065
Gastroenterology. 2015 Apr;148(4):849-50
pubmed: 25724458